Conduit Pharmaceuticals Files 8-K on Security Holder Rights
Ticker: CDTTW · Form: 8-K · Filed: Jan 23, 2025 · CIK: 1896212
| Field | Detail |
|---|---|
| Company | Conduit Pharmaceuticals Inc. (CDTTW) |
| Form Type | 8-K |
| Filed Date | Jan 23, 2025 |
| Risk Level | medium |
| Pages | 4 |
| Reading Time | 5 min |
| Key Dollar Amounts | $0.0001, $11.50 |
| Sentiment | neutral |
Sentiment: neutral
Topics: corporate-governance, filing-update
Related Tickers: CDT
TL;DR
Conduit Pharma (CDT) filed an 8-K detailing changes to security holder rights and corporate bylaws.
AI Summary
Conduit Pharmaceuticals Inc. filed an 8-K on January 23, 2025, reporting material modifications to the rights of security holders and amendments to its articles of incorporation or bylaws. The filing also includes Regulation FD disclosures and financial statements/exhibits. The company, formerly known as Murphy Canyon Acquisition Corp. until November 30, 2021, is incorporated in Delaware and its fiscal year ends on December 31.
Why It Matters
This filing indicates potential changes to the rights associated with Conduit Pharmaceuticals' securities, which could impact investors' ownership and voting privileges.
Risk Assessment
Risk Level: medium — Filings related to modifications of security holder rights and amendments to corporate bylaws can introduce new risks or alter existing ones for investors.
Key Players & Entities
- Conduit Pharmaceuticals Inc. (company) — Registrant
- Murphy Canyon Acquisition Corp. (company) — Former Company Name
- January 22, 2025 (date) — Earliest event reported
- January 23, 2025 (date) — Filing Date
- November 30, 2021 (date) — Date of name change
FAQ
What specific modifications were made to the rights of security holders?
The filing indicates 'Material Modifications to Rights of Security Holders' as an item of disclosure, but the specific details of these modifications are not provided in the provided text excerpt.
What amendments were made to Conduit Pharmaceuticals' articles of incorporation or bylaws?
The filing lists 'Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year' as an item, but the specific amendments are not detailed in the excerpt.
When did Conduit Pharmaceuticals Inc. change its name from Murphy Canyon Acquisition Corp.?
Conduit Pharmaceuticals Inc. changed its name from Murphy Canyon Acquisition Corp. on November 30, 2021.
What is Conduit Pharmaceuticals Inc.'s fiscal year end?
Conduit Pharmaceuticals Inc.'s fiscal year ends on December 31.
What is the SEC file number for Conduit Pharmaceuticals Inc.?
The SEC file number for Conduit Pharmaceuticals Inc. is 001-41245.
Filing Stats: 1,127 words · 5 min read · ~4 pages · Grade level 11.1 · Accepted 2025-01-23 08:15:20
Key Financial Figures
- $0.0001 — nge on which registered Common Stock, $0.0001 par value per share CDT The Nasdaq
- $11.50 — of Common Stock at an exercise price of $11.50 CDTTW The Nasdaq Stock Market LLC
Filing Documents
- form8-k.htm (8-K) — 51KB
- ex3-1.htm (EX-3.1) — 15KB
- ex99-1.htm (EX-99.1) — 14KB
- 0001493152-25-003316.txt ( ) — 314KB
- cdt-20250122.xsd (EX-101.SCH) — 4KB
- cdt-20250122_def.xml (EX-101.DEF) — 29KB
- cdt-20250122_lab.xml (EX-101.LAB) — 36KB
- cdt-20250122_pre.xml (EX-101.PRE) — 27KB
- form8-k_htm.xml (XML) — 6KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. CONDUIT PHARMACEUTICALS INC. January 23, 2025 By: /s/ David Tapolczay Name: David Tapolczay Title: Chief Executive Officer